Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Appointed director

Inmune Bio, Inc. (INMB) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/15/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "About INKmune"
05/20/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "www.inmunebio.com. Forward Looking Statements"
05/18/2020 8-K Investor presentation
Docs: "Corporate Presentation"
05/15/2020 8-K Quarterly results
Docs: "CONSOLIDATED BALANCE SHEETS"
05/12/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Forward Looking Statements"
05/07/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "[email protected] Investor Contact: James Carbonara 755-7412 [email protected]"
05/05/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Presentation"
04/28/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "[email protected]"
04/24/2020 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
04/23/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Forward Looking Statements"
04/22/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells GlobeNewswire April 22, 2020"
04/21/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Transcript of the INmune Bio Inc. Conference Call on April 20, 2020"
04/21/2020 EFFECT Form EFFECT - Notice of Effectiveness:
04/14/2020 POS AM Form POS AM - Post-Effective amendments for registration statement:
04/09/2020 8-K Investor presentation
Docs: "Presentation",
"Summary"
04/03/2020 EFFECT Form EFFECT - Notice of Effectiveness:
03/24/2020 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/12/2020 8-K Quarterly results
03/10/2020 10-K Annual Report for the period ended December 31, 2019
03/09/2020 8-K Quarterly results
03/04/2020 8-K Quarterly results
02/14/2020 SC 13D/A Tesi Raymond Joseph reports a 17.7% stake in INMUNE BIO INC.
02/14/2020 SC 13D/A Moss David J reports a 14.8% stake in INMUNE BIO INC.
02/14/2020 SC 13D/A Lowdell Mark William reports a 17.2% stake in INMUNE BIO INC.
02/14/2020 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/10/2020 8-K Quarterly results
01/27/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Common Stock Repurchase Agreement"
01/13/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INmune Bio Fact Sheet",
"INmune Slide Presentation"
01/02/2020 8-K Quarterly results
12/17/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INMUNE BIO PRESS RELEASE DATED DECEMBER 2, 2019"
12/03/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "INMUNE BIO PRESS RELEASE DATED DECEMBER 2, 2019"
11/29/2019 8-K Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Ce...
Docs: "INmune Bio’ s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’ s drug development."
11/20/2019 8-K Quarterly results
11/12/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy